Back
 Health  Vol.10 No.5 , May 2018
Polycystic Ovary Syndrome and the Role of Metformin in Ovulation Induction
Abstract: The Polycystic Ovary Syndrome (PCOS) is frequently associated with comorbidities such as obesity, reduced glucose tolerance, hypertension, macrovascular disease and dyslipidemia. The Metabolic syndrome occurs in 30% of women with PCOS. Metformin has increasingly been used in this therapy due to its effects in reducing insulin resistance. Treatment of PCOS aims to reduce the symptoms of hyperandrogenism, regularize the menstrual cycle, reduce metabolic abnormalities, and lower the risk of type 2 diabetes mellitus and of cardiovascular disease. Additionally it is important to prevent hyperplasia and endometrial cancer, and to offer contraception to those who do not wish pregnancy, and to help to induce ovulation to those who do. The effectiveness of metformin in this treatment is assessed in the light of the current best evidence.
Cite this paper: Fraga, F. , Romeiro, G. , Bianca Paiva Cunha de Sá, L. , Krayyem Arbex, A. (2018) Polycystic Ovary Syndrome and the Role of Metformin in Ovulation Induction. Health, 10, 565-576. doi: 10.4236/health.2018.105045.
References

[1]   Rosenfield, R.L. and Ehrmann, D.A. (2016) The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 2016, 367.
https://doi.org/10.1210/er.2015-1104

[2]   Pontes, A. and Filho, B.S.A. (2016) Polycystic Ovarian Syndrome: Diagnosis, Treatment and Repercussions throughout Life. UNESP, Botucatu.

[3]   Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H.F., Futterweit, W., Janssen, O.E., Legro, R.S., Norman, R.J., Taylor, A.E. and Witchel, S.F. and Androgen Excess Society (2006) Positions Statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. The Journal of Clinical Endocrinology & Metabolism, 91, 4237-4245.
https://doi.org/10.1210/jc.2006-0178

[4]   Ning, N., Balen, A., Brezina, P.R., Leong, M., Shoham, Z., Wallach, E.E. and Zhao, Y. (2013) How to Recognize PCOS: Results of a Web-Based Survey at IVF-Worldwide.com. Reproductive Biomedicine, 26, 500-505.
https://doi.org/10.1016/j.rbmo.2013.01.009

[5]   Sam, S., Legro, R.S., Essah, P.A., et al. (2006) Evidence for Metabolic and Reproductive Phenotypes in Mothers of Women with Polycystic Ovary Syndrome. Proceedings of the National Academy of Sciences of the United States, 103, 7030.
https://doi.org/10.1073/pnas.0602025103

[6]   Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. (2013) Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 98, 4565.
https://doi.org/10.1210/jc.2013-2350

[7]   Costa, L.O.B.F., Viana, A.O.R. and Oliveira, M. (2007) Prevalence of Metabolic Syndrome in Patients with Polycystic Ovary Syndrome. Revista Brasileira de Ginecologia e Obstetrícia 29, 10-17.

[8]   Twig, G., Yaniv, G., Levine, H., et al. (2016) Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. The New England Journal of Medicine, 374, 2430.
https://doi.org/10.1056/NEJMoa1503840

[9]   Fauser, B.C. and Bouchard, P. (2011) Uncertainty Remains in Women with PCOS Regarding the Increased Incidence of Cardiovascular Disease Later in Life, despite the Indisputable Presence of Multiple Cardiovascular Risk Factors at a Young Age. The Journal of Clinical Endocrinology & Metabolism, 96, 3675.
https://doi.org/10.1210/jc.2011-2935

[10]   Robert, L. and Rosenfield, M.D. (2017) Etiology and Pathophysiology of Polycystic Ovary Syndrome in Adolescents.
https://www.uptodate.com/contents/etiology-and-pathophysiology-of-polycystic-ovary-syndrome-in-adolescents

[11]   Moran, L.J., Hutchison, S.K., Norman, R.J. and Teede, H.J. (2011) Lifestyle Changes in Women with Polycystic Ovary Syndrome. The Cochrane Database of Systematic Reviews, 2011, Article ID: CD007506.
https://doi.org/10.1002/14651858.CD007506.pub3

[12]   Pasquali, R., Antenucci, D., Casimirri, F., et al. (1989) Clinical and Hormonal Characteristics of Obese Amenorrheic Hyperandrogenic Women before and after Weight Loss. The Journal of Clinical Endocrinology & Metabolism, 68, 173.
https://doi.org/10.1210/jcem-68-1-173

[13]   Huber-Buchholz, M.M., Carey, D.G. and Norman, R.J. (1999) Restoration of Reproductive Potential by Lifestyle Modification in Obese Polycystic Ovary Syndrome: Role of Insulin Sensitivity and Luteinizing Hormone. The Journal of Clinical Endocrinology & Metabolism, 84, 1470.

[14]   Barbieri, R.L. and Ehrmann, D.A. (2017) Treatment of Polycystic Ovary Syndrome in Adults.
https://www.uptodate.com/contents/treatment-of-polycystic-ovary-syndrome-in-adults

[15]   Dumesic, D.A. and Lobo, R.A. (2013) Cancer Risk and PCOS. Steroids, 78, 782.
https://doi.org/10.1016/j.steroids.2013.04.004

[16]   Nestler, J.E. (2008) Metformin for the Treatment of the Polycystic Ovary Syndrome. The New England Journal of Medicine, 358, 47-54.
https://doi.org/10.1056/NEJMct0707092

[17]   Morley, L.C., et al. (2017) Metformin Therapy for the Management of Infertility in Women with Polycystic Ovary Syndrome: Scientific Impact Paper No. 13. BJOG, 124, e306.
https://doi.org/10.1111/1471-0528.14764

[18]   Ferrannini, E. (2014) The Target of Metformin in Type 2 Diabetes. The New England Journal of Medicine, 371, 1547-1548.
https://doi.org/10.1056/NEJMcibr1409796

[19]   Madiraju, A.K., Erion, D.M., Rahimi, Y., et al. (2014) Metformin Suppresses Gluconeogenesis by Inhibiting Mitochondrial Glycerophosphate Dehydrogenase. Nature, 510, 542-546.
https://doi.org/10.1038/nature13270

[20]   Barbieri, R.L. and Ehrmann, D.A. (2017) Metformin for Treatment of the Polycystic Ovary Syndrome.

[21]   Niafar, M., Hai, F., Porhomayon, J. and Nader, N.D. (2015) The Role of Metformin on Vitamin B12 Deficiency: A Meta-Analysis Review. Internal and Emergency Medicine, 10, 93-102.
https://doi.org/10.1007/s11739-014-1157-5

[22]   Kocak, M., Caliskan, E., Simsir, C. and Haberal, A. (2002) Metformin Therapy Improves Ovulatory Rates, Cervical Scores, and Pregnancy Rates in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome. Fertility and Sterility, 77, 101-106.
https://doi.org/10.1016/S0015-0282(01)02941-7

[23]   Vandermolen, D.T., Ratts, V.S., Evans, W.S., et al. (2001) Metformin Increases the Ovulatory Rate and Pregnancy Rate from Clomiphene Citrate in Patients with Polycystic Ovary Syndrome Who Are Resistant to Clomiphene Citrate Alone. Fertility and Sterility, 75, 310-315.
https://doi.org/10.1016/S0015-0282(00)01675-7

[24]   Moghetti, P., Castello, R., Negri, C., et al. (2000) Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, Followed by Open, Long-Term Clinical Evaluation. The Journal of Clinical Endocrinology & Metabolism, 85, 139-146.

[25]   Unlühizarci, K., Kelestimur, F., Bayram, F., et al. (1999) The Effects of Metformin on Insulin Resistance and Ovarian Steroidogenesis in Women with Polycystic Ovary Syndrome. Clinical Endocrinology, 51, 231-236.
https://doi.org/10.1046/j.1365-2265.1999.00786.x

[26]   Tang, T., Lord, J.M., Norman, R.J., et al. (2012) Insulin-Sensitising Drugs (Metformin, Rosiglitazone, Pioglitazone, D-Chiro-Inositol) for Women with Polycystic Ovary Syndrome, Oligo Amenorrhoea and Subfertility. The Cochrane Database of Systematic Reviews, No. 1, CD003053.

[27]   Palomba, S., Orio, F.J., Falbo, A., Russo, T., Tolino, A. and Zullo, F. (2007) Clomiphene Citrate versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 92, 3498-3503.
https://doi.org/10.1210/jc.2007-1009

[28]   Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M., et al. (2000) Endocrine and Metabolic Effects of Metformin versus Ethinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study. The Journal of Clinical Endocrinology & Metabolism, 85, 3161-3168.
https://doi.org/10.1210/jc.85.9.3161

[29]   Costello, M., Shrestha, B., Eden, J., et al. (2007) Insulin-Sensitising Drugs versus the Combined Oral Contraceptive Pill for Hirsutism, Acne and Risk of Diabetes, Cardiovascular Disease, and Endometrial Cancer in Polycystic Ovary Syndrome. The Cochrane Database of Systematic Reviews, No. 1, CD005552.

[30]   Tso, L.O., Costello, M.F., Albuquerque, L.E., et al. (2009) Metformin Treatment before and during IVF or ICSI in Women with Polycystic Ovary Syndrome. The Cochrane Database of Systematic Reviews, 11, CD006105.

[31]   Palomba, S., Falbo, A. and La Sala, G.B. (2013) Effects of Metformin in Women with Polycystic Ovary Syndrome Treated with Gonadotrophins for in Vitro Fertilisation and Intracytoplasmic Sperm Injection Cycles: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. BJOG, 120, 267-276.
https://doi.org/10.1111/1471-0528.12070

[32]   Palomba, S., Falbo, A., Carrillo, L., et al. (2011) Metformin Reduces Risk of Ovarian Hyperstimulation Syndrome in Patients with Polycystic Ovary Syndrome during Gonadotropin-Stimulated in Vitro Fertilization Cycles: A Randomized, Controlled Trial. Fertility and Sterility, 96, 1384-1390.
https://doi.org/10.1016/j.fertnstert.2011.09.020

[33]   Al-Inany, H.G., Youssef, M.A., Ayeleke, R.O., et al. (2016) Gonadotrophin-Releasing Hormone Antagonists for Assisted Reproductive Technology. The Cochrane Database of Systematic Reviews, 4, CD001750.
https://doi.org/10.1002/14651858.CD001750.pub4

[34]   Practice Committee of the American Society for Reproductive Medicine, Practice Committee of the American Society for Reproductive Medicine (2017) Role of Metformin for Ovulation Induction in Infertile Patients with Polycystic Ovary Syndrome (PCOS): A Guideline. Fertility and Sterility, 108, 426-441.
https://doi.org/10.1016/j.fertnstert.2017.06.026

[35]   Lord, J.M., Flight, I.H. and Norman, R.J. (2003) Insulin-Sensitising Drugs (Metformin, Troglitazone, Rosiglitazone, Pioglitazone, D-Chiro-Inositol) for Polycystic Ovary Syndrome. The Cochrane Database of Systematic Reviews, No. 3, CD003053.

[36]   Pasquali, R., Gambineri, A., Biscotti, D., et al. (2000) Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without the Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 85, 2767-2774.
https://doi.org/10.1210/jcem.85.8.6738

[37]   Kay, J.P., Alemzadeh, R., Langley, G., et al. (2001) Beneficial Effects of Metformin in Normoglycemic Morbidly Obese Adolescents. Metabolism, 50, 1457-1461.
https://doi.org/10.1053/meta.2001.28078

[38]   Freemark, M. and Bursey, D. (2001) The Effects of Metformin on Body Mass Index and Glucose Tolerance in Obese Adolescents with Fasting Hyperinsulinemia and a Family History of Type 2 Diabetes. Pediatrics, 107, e55.
https://doi.org/10.1542/peds.107.4.e55

[39]   Harborne, L.R., Sattar, N., Norman, J.E. and Fleming, R. (2005) Metformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses. The Journal of Clinical Endocrinology & Metabolism, 90, 4593-4598.
https://doi.org/10.1210/jc.2004-2283

[40]   Rowan, J.A., Hague, W.M., Gao, W., Battin, M.R. and Moore, M.P. (2008) Metformin versus Insulin for the Treatment of Gestational Diabetes. The New England Journal of Medicine, 358, 2003-2015.
https://doi.org/10.1056/NEJMoa0707193

[41]   Morin-Papunen, L., Rantala, A.S., Unkila-Kallio, L., Tiitinen, A., Hippelainen, M., Perheentupa, A., Tinkanen, H., Bloigu, R., Puukka, K., Ruokonen, A. and Tapanainen, J.S. (2012) Metformin Improves Pregnancy and Live-Birth Rates in Women with Polycystic Ovary Syndrome (PCOS): A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial. The Journal of Clinical Endocrinology & Metabolism, 97, 1492-1500.
https://doi.org/10.1210/jc.2011-3061

 
 
Top